The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

Journal of the Canadian Urological Association

Volumn 3, Issue 3 SUPPL. 2, 2009, Pages

  Goldenberg, Larry ^a   So, Alan ^a   Fleshner, Neil ^b   Rendon, Ricardo ^c   Drachenberg, Darrel ^d   Elhilali, Mostafa ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72049121194     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012-21.
2. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan- 17-beta-ol-3-one by rat prostate. J Biol Chem 1968; 243: 5953-60.
3. Anderson KM, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature 1968; 219: 277-9.
4. Hudak SJ, Hernandez J, Thompson IM. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging 2006; 1: 425-31.
5. Imamoto T, Suzuki H, Yano M, et al. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 2008; 15: 472-80.
6. Thomas LN, Douglas RC, Lazier CB, et al. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53: 244-52.
7. Chu LW, Reichardt JK, Hsing AW. Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008; 15: 261-70.
8. Wright AS, Douglas RC, Thomas LN, et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 1999; 140: 4509-15.
9. Dadras SS, Cai X, Abasolo I, et al. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr 2001; 9: 183-94.
10. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63: 231-9.
11. Iehlé C, Radvanyi F, Gil Diez de Medina S, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-95.
12. Titus MA, Gregory CW, Ford OH 3rd, et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4365-71.
13. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5alpha-reductase type 1 and type are increased in localized high grade compared to low grade prostate cancer. J Urol 2008; 179: 147-51.
14. Xu Y, Dalrymple SL, Becker RE, et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006; 12: 4072-9.
15. Rittmaster RS. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008; 22: 389-402.
16. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84.
17. Roehrborn C, Ray P, Gittelmann M, et al. The novel dual 5 alpha-reductase inhibitor, dutasteride, is effective and well-tolerated for benign prostatic hyperplasia in black men. [poster 635]. European Urology Association Annual Meeting; Madrid; 12-15 March, 2003.
18. Djavan B, Mirone V. The benefits of dual inhibition of 5 alpha reductase. Eur Urol Suppl 2006; 5: 1013.
19. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 2006; 66: 1674-85.
20. Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005; 65: 76-82.
21. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-78.
22. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Longterm Efficacy and Safety Study. Urology 1998; 52: 195-201.
23. Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868-74.
24. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126: 1165-72.
25. Uemura M, Tamura K, Chung S, et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99: 81-6.
26. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
27. Akduman B, Crawford ED. The PCPT: New findings, new insights, and clinical implications for the prevention of prostate cancer. Eur Urol Suppl 2006; 5: 634.
28. Musquera M, Fleshner NE, Finelli A, et al. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008; 8: 1073-9.
29. Makridakis N, Akalu A, Reichardt JK. dentification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. ncogene 2004; 3: 399-405.
30. Makridakis N, Reichardt JK. harmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. Mol Endocrinol 2005; 4: 17-23.
31. Eggener SE, Stern JA, Jain PM, et al. nhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. rostate 2006; 6: 95-502.
32. Scher HI, Buchanan G, Gerald W, et al. argeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. ndocr Relat Cancer 2004; 1: 59-76.
33. aximal suppression of the androgen axis in clinically localized prostate cancer (NCT00298155). http://www.clinicaltrials.gov/ct2/show/NCT00298155?term= nct00298155&rank=1.accessed January 16, 2009.
34. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. ancer Res 2008; 8: 407-15.